FDAShortage list
FDA reaffirms the tirzepatide shortage is resolved
After a short reconsideration, the FDA reaffirmed that the tirzepatide shortage was over, again requiring compounders to wind down production of copies. As with semaglutide, removal from the shortage list removes the basis that permitted compounded tirzepatide, tightening the supply of versions sold outside the approved products.
Source
https://www.fda.gov/drugs/drug-safety-and-availability/drug-shortagesThe issuing body’s own page is authoritative. PepIndex records what it says and when we recorded it; where the two disagree, the source governs.